	US 11,866,476 B2
	Masked IL-2-Fc fusion polypeptides
Margaret Karow, Santa Rosa Valley, CA (US); Deborah Moore Lai, Beverly, MA (US); Dheeraj Tomar, Dorchester, MA (US); Parker Johnson, Allston, MA (US); Raphael Rozenfeld, Newton, MA (US); Ronan O'Hagan, Waltham, MA (US); and Huawei Qiu, Westborough, MA (US)
Assigned to Xilio Development, Inc., Waltham, MA (US)
Filed by Xilio Development, Inc., Waltham, MA (US)
Filed on Dec. 28, 2022, as Appl. No. 18/089,754.
Application 18/089,754 is a continuation of application No. 17/716,873, filed on Apr. 8, 2022.
Application 17/716,873 is a continuation of application No. 17/279,407, previously published as PCT/US2019/053588, filed on Sep. 27, 2019.
Claims priority of provisional application 62/891,199, filed on Aug. 23, 2019.
Claims priority of provisional application 62/888,276, filed on Aug. 16, 2019.
Claims priority of provisional application 62/737,803, filed on Sep. 27, 2018.
Prior Publication US 2023/0235006 A1, Jul. 27, 2023
Int. Cl. C07K 14/55 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/55 (2013.01) [A61P 35/00 (2018.01); C07K 14/5443 (2013.01); A61K 38/00 (2013.01); C07K 2317/52 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01)]

10 Claims

1. A masked cytokine comprising:

a) a first polypeptide comprising a first half-life extension domain and a masking moiety and

b) a second polypeptide comprising a second half-life extension domain and a cytokine;

wherein the first half-life extension domain is a first Fc domain or fragment thereof, and the second half-life extension domain is a second Fc domain or fragment thereof;

wherein the masking moiety comprises an amino acid sequence of SEQ ID NO: 826

wherein the cytokine is an IL-2 polypeptide comprising the amino acid sequence of SEQ ID NO: 3;

wherein the masking moiety is linked to the C-terminus of the first half-life extension domain via a first linker;

wherein the cytokine is linked to the C-terminus of the second half-life extension domain via a second linker, wherein the second linker comprises a cleavable peptide; and

wherein the first half-life extension domain and the second half-life extension domain contain modifications promoting the association of the first and the second half-life extension domain.